Istesso starts trial of leramistat in sarcopenia

IP Group’s update is all promise, no proof—wait for real clinical results.

What the company is saying

IP Group plc is positioning itself as a leader in breakthrough medical innovation by highlighting the commencement of a Phase 2 clinical trial for leramistat, its portfolio company Istesso’s lead drug candidate. The company’s narrative is that leramistat could address sarcopenia caused by rheumatoid arthritis, a condition they claim is a major unmet need with no current pharmacological therapies. They frame the trial as a rigorous, randomised, double-blind, placebo-controlled study, and reference prior data suggesting leramistat improved disability and fatigue, though no actual figures or study details are provided. The announcement leans heavily on the idea that leramistat’s mechanism—modulating mitochondrial function—could unlock broad tissue repair and regeneration, with potential applications across muscle, bone, gut, and lung. IP Group emphasizes its 56.5% undiluted holding in Istesso, suggesting strong alignment and upside if the trial succeeds. The language is highly aspirational, with phrases like “we are the only company to understand and exploit the body’s natural biology of repair” and “almost 1,000 years of drug discovery expertise,” but these are not substantiated with evidence or specifics. The announcement is upbeat and confident, projecting scientific authority and a sense of inevitability about success, but it omits any discussion of risks, trial size, endpoints, timelines, or financial exposure. Notable individuals such as Greg Smith (Chief Executive of IP Group) are named, but their involvement is limited to corporate roles, not direct scientific or financial endorsement of the trial. This narrative fits IP Group’s broader strategy of presenting itself as a backer of world-changing university spinouts, but the messaging here is more promotional than substantive, with no notable shift from prior communications due to lack of historical context.

What the data suggests

The only hard data disclosed is that IP Group holds a 56.5% undiluted stake in Istesso and that dosing has begun in a Phase 2 trial for leramistat. There are no financial figures—no revenue, profit, R&D spend, or cash burn—so it is impossible to assess the financial trajectory or health of either IP Group or Istesso from this announcement. No patient numbers, trial duration, or endpoints are provided, making it impossible to gauge the scale or ambition of the study. Claims about prior clinical and preclinical success are made, but no quantitative results, p-values, or even summary statistics are shared, so investors cannot independently assess the strength of the evidence. There is no mention of whether previous targets or milestones have been met, missed, or delayed. The quality of disclosure is poor: key metrics are missing, and the announcement is structured to maximize positive sentiment while minimizing hard facts. An independent analyst would conclude that, based on the numbers alone, the only verifiable progress is the start of a Phase 2 trial and the size of IP Group’s stake—everything else is unsubstantiated narrative.

Analysis

The announcement is positive in tone, highlighting the commencement of a Phase 2 clinical trial for leramistat and referencing prior preclinical and clinical data. However, most of the key claims are either forward-looking or based on unquantified prior results, with no new clinical efficacy or safety data disclosed. The language is aspirational, suggesting broad future impact and unique capabilities, but the only realised milestone is the start of patient dosing and ongoing enrolment. There is no disclosure of trial size, endpoints, timelines, or financial commitment, and no immediate earnings or value impact is implied. The gap between narrative and evidence is moderate: the company frames the trial as a major step, but measurable progress is limited to trial initiation. The absence of capital outlay or funding details means the capital intensity flag is not triggered.

Risk flags

• ●The majority of claims are forward-looking, hinging on the success of a Phase 2 trial that has only just begun. This means investors are being asked to buy into a narrative with no near-term proof points, exposing them to significant clinical and execution risk.
• ●There is a complete absence of financial disclosure—no trial costs, funding sources, or burn rates are provided. This lack of transparency makes it impossible to assess whether Istesso or IP Group can sustain the trial through completion, or what the financial downside might be if the trial fails.
• ●No clinical endpoints, patient numbers, or trial duration are disclosed, making it impossible to judge whether the study is adequately powered or designed to deliver meaningful results. This raises the risk that even a completed trial may not yield actionable or regulatory-relevant data.
• ●The announcement relies on unsubstantiated claims of prior clinical and preclinical success, with no data or peer-reviewed evidence provided. This pattern of hype without proof is a classic red flag for investors, as it suggests management is prioritizing narrative over substance.
• ●The company makes grandiose statements about uniqueness and expertise—such as being the only company to exploit the body’s natural biology of repair and having 'almost 1,000 years' of experience—without any breakdown or supporting evidence. Such hyperbole often signals a lack of real competitive differentiation.
• ●No discussion of risks, adverse events, or potential for trial failure is included, which is atypical for a credible clinical-stage update. This omission suggests management is not preparing investors for downside scenarios, increasing the risk of negative surprises.
• ●There is no mention of regulatory engagement, commercial partnerships, or external validation, which are critical for de-risking a biotech asset at this stage. The absence of these elements means the company is still at a very early, high-risk phase.
• ●Notable individuals are named in corporate roles, but there is no evidence of external institutional validation or investment in this specific trial. This limits the credibility of the narrative and means investors cannot rely on third-party due diligence.

Bottom line

For investors, this announcement is little more than a flag that Istesso’s leramistat has entered Phase 2 testing for a new indication—sarcopenia in rheumatoid arthritis—under the majority ownership of IP Group. The company’s narrative is highly promotional, but the lack of clinical data, financial disclosure, or trial specifics means there is no way to independently assess the likelihood of success or the potential value creation. The only hard facts are the start of dosing and the 56.5% stake; everything else is hope and marketing. No notable institutional investors or partners are backing this trial, so there is no external validation to lean on. To change this assessment, the company would need to release concrete clinical results, specify trial endpoints and timelines, and provide transparent financials. Investors should watch for interim data releases, trial completion dates, and any sign of regulatory or commercial interest in the next reporting period. At this stage, the information is not actionable for a serious investment decision—it is a weak signal worth monitoring, not acting on. The single most important takeaway is that until real clinical data emerges, all value here is speculative and the risk of disappointment is high.

Announcement summary

(LSE: IPO) IP Group plc announced that its portfolio company Istesso has commenced dosing in IST-03, a Phase 2 clinical trial of its lead candidate, leramistat, in patients with sarcopenia caused by rheumatoid arthritis. The randomised, double-blind, placebo-controlled study is evaluating the effects of leramistat on muscle quality, repair and function. The clinical study builds on prior rheumatoid arthritis data showing leramistat improved disability and fatigue alongside reductions in markers of muscle loss. Preclinical findings showed restoration of muscle quality in disease models and recovery of muscle mass, quality and function in aged animals to levels greater than those seen in baseline younger animals. IP Group has an undiluted holding of 56.5% in Istesso. Enrolment is currently underway at Newcastle University and Newcastle Hospitals, in conjunction with the National Institute for Health and Care Research (NIHR). The company states that the aim of the study is to show that it is possible to augment the human capacity to repair, and that success would have implications for the treatment of chronic degenerative and age-related diseases.

Disagree with this article?